Gastrointestinal cancers: current biomarkers in esophageal and gastric adenocarcinoma

被引：34

作者：

Dhakras, Purabi ^{[1
]}

Uboha, Nataliya ^{[2
,3
,4
]}

Horner, Vanessa ^{[1
,5
]}

Reinig, Erica ^{[1
]}

Matkowskyj, Kristina A. ^{[1
,3
,4
]}

机构：

[1] Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI USA

[2] Univ Wisconsin, Dept Med, Div Hematol Med Oncol & Palliat Care, Madison, WI USA

[3] UW Carbone Canc Ctr, Madison, WI USA

[4] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA

[5] Wisconsin State Lab Hyg, Madison, WI USA

来源：

TRANSLATIONAL GASTROENTEROLOGY AND HEPATOLOGY | 2020年 / 5卷

关键词：

Human epidermal growth factor receptor 2 (HER2); microsatellite instability (MSI); program death-ligand 1 (PD-L1); DNA MISMATCH REPAIR; SHORT-TERM PROGNOSIS; CELL LUNG-CANCER; MICROSATELLITE INSTABILITY; GENE AMPLIFICATION; FAMILIAL PREDISPOSITION; INTERNATIONAL CRITERIA; INSTITUTE WORKSHOP; PD-L1; EXPRESSION; C-ERBB-2; PROTEIN;

D O I：

10.21037/tgh.2020.01.08

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Esophageal and gastric adenocarcinomas are frequently diagnosed at an advanced stage and have a dismal prognosis. Even in patients with potentially curative cancer, nearly 50% will develop recurrent disease despite aggressive treatments. A number of biomarkers currently guide treatment decisions for patients with esophageal and gastric adenocarcinoma and include human epidermal growth factor receptor 2 (HER2) amplification, mismatch repair deficiency/microsatellite instability (dMMR/MSI-H) and program death-ligand 1 (PD-L1) expression. This review will focus on the function, testing and FDA-approved targeted therapies for HER2, dMMR/MSI-H and PD-L1. In addition, a number of novel targets in esophageal and gastric cancer are being studied in clinical trials. Neurotrophic-tropomyosin receptor kinase (NTRK), claudin-18 (CLDN18)/Rho GTPase activating protein 26 (ARHGAP26) gene fusion, fibroblast growth factor receptor (FGFR), lymphocyte-activation gene 3 (LAG3) and T cell immunoglobulin and mucin-domain containing-3 (TIM3) will be briefly reviewed. Despite several biomarkers used in the selection of treatment therapies, treatment outcomes remain poor. Future research efforts will focus on the identification of new biomarkers, moving existing biomarkers into earlier lines of therapy, and evaluating new combinations of existing biomarkers and therapies.

引用

页数：12

共 78 条

[11] Functional interactions and signaling properties of mammalian DNA mismatch repair proteins [J].

Bellacosa, A .

CELL DEATH AND DIFFERENTIATION, 2001, 8 (11) :1076-1092

[12]

Boland CR, 1998, CANCER RES, V58, P5248

[13] THE C-ERB-2 PROTEIN IN ONCOGENESIS - MOLECULAR-STRUCTURE TO MOLECULAR EPIDEMIOLOGY [J].

BRANDTRAUF, PW ;

PINCUS, MR ;

CARNEY, WP .

CRITICAL REVIEWS IN ONCOGENESIS, 1994, 5 (2-3) :313-329

[14] Risk and Epidemiological Time Trends of Gastric Cancer in Lynch Syndrome Carriers in The Netherlands [J].

Capelle, Lisette G. ;

Van Grieken, Nicole C. T. ;

Lingsma, Hester F. ;

Steyerberg, Ewout W. ;

Klokman, Willem J. ;

Bruno, Marco J. ;

Vasen, Hans F. A. ;

Kuipers, Ernst J. .

GASTROENTEROLOGY, 2010, 138 (02) :487-492

[15] PD-L1 expression as a predictive biomarker for cytokine-induced killer cell immunotherapy in patients with hepatocellular carcinoma [J].

Chen, Chang-Long ;

Pan, Qiu-Zhong ;

Zhao, Jing-Jing ;

Wang, Ying ;

Li, Yong-Qiang ;

Wang, Qi-Jing ;

Pan, Ke ;

Weng, De-Sheng ;

Jiang, Shan-Shan ;

Tang, Yan ;

Zhang, Xiao-Fei ;

Zhang, Hong-Xia ;

Zhou, Zi-Qi ;

Zeng, Yi-Xin ;

Xia, Jian-Chuan .

ONCOIMMUNOLOGY, 2016, 5 (07)

[16] Microsatellite Instability and Programmed Cell Death-Ligand 1 Expression in Stage II/III Gastric Cancer Post Hoc Analysis of the CLASSIC Randomized Controlled study [J].

Choi, Yoon Young ;

Kim, Hyunki ;

Shin, Su-Jin ;

Kim, Ha Yan ;

Lee, Jinae ;

Yang, Han-Kwang ;

Kim, Woo Ho ;

Kim, Young-Woo ;

Kook, Myeong-Cherl ;

Park, Young Kyu ;

Kim, Hyung-Ho ;

Lee, Hye Seung ;

Lee, Kyung Hee ;

Gu, Mi Jin ;

Choi, Seung Ho ;

Hong, SoonWon ;

Kim, Jong Won ;

Hyung, Woo Jin ;

Noh, Sung Hoon ;

Cheong, Jae-Ho .

ANNALS OF SURGERY, 2019, 270 (02) :309-316

[17] Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes [J].

Cristescu, Razvan ;

Lee, Jeeyun ;

Nebozhyn, Michael ;

Kim, Kyoung-Mee ;

Ting, Jason C. ;

Wong, Swee Seong ;

Liu, Jiangang ;

Yue, Yong Gang ;

Wang, Jian ;

Yu, Kun ;

Ye, Xiang S. ;

Do, In-Gu ;

Liu, Shawn ;

Gong, Lara ;

Fu, Jake ;

Jin, Jason Gang ;

Choi, Min Gew ;

Sohn, Tae Sung ;

Lee, Joon Ho ;

Bae, Jae Moon ;

Kim, Seung Tae ;

Park, Se Hoon ;

Sohn, Insuk ;

Jung, Sin-Ho ;

Tan, Patrick ;

Chen, Ronghua ;

Hardwick, James ;

Kang, Won Ki ;

Ayers, Mark ;

Dai Hongyue ;

Reinhard, Christoph ;

Loboda, Andrey ;

Kim, Sung ;

Aggarwal, Amit .

NATURE MEDICINE, 2015, 21 (05) :449-U217

[18]

Dong HD, 1999, NAT MED, V5, P1365

[19] Defective mismatch-repair as a minor turnorigenic pathway in Barrett esophagus-associated adenocarcinorna [J].

Falkenback, D ;

Johansson, J ;

Halvarsson, B ;

Nilbert, M .

CANCER GENETICS AND CYTOGENETICS, 2005, 157 (01) :82-86

[20] Clinicopathologic and Molecular Profiles of Microsatellite Unstable Barrett Esophagus-associated Adenocarcinoma [J].

Farris, Alton B., III ;

Demicco, Elizabeth G. ;

Le, Long Phe ;

Finberg, Karin E. ;

Miller, Julie ;

Mandal, Rajni ;

Fukuoka, Junya ;

Cohen, Cynthia ;

Gaissert, Henning A. ;

Zukerberg, Lawrence R. ;

Lauwers, Gregory Y. ;

Iafrate, A. John ;

Mino-Kenudson, Mari .

AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2011, 35 (05) :647-655

← 1 2 3 4 5 6 7 8 →